Abstract
OBJECTIVE: This study aimed to construct a multimodal imaging deep learning (DL) model integrating mpMRI and (18)F-PSMA-PET/CT for the prediction of extraprostatic extension (EPE) in prostate cancer, and to assess its effectiveness in enhancing the diagnostic accuracy of radiologists. METHODS: Clinical and imaging data were retrospectively collected from patients with pathologically confirmed prostate cancer (PCa) who underwent radical prostatectomy (RP). Data were collected from a primary institution (Center 1, n = 197) between January 2019 and June 2022 and an external institution (Center 2, n = 36) between July 2021 and November 2022. A multimodal DL model incorporating mpMRI and (18)F-PSMA-PET/CT was developed to support radiologists in assessing EPE using the EPE-grade scoring system. The predictive performance of the DL model was compared with that of single-modality models, as well as with radiologist assessments with and without model assistance. Clinical net benefit of the model was also assessed. RESULTS: For patients in Center 1, the area under the curve (AUC) for predicting EPE was 0.76 (0.72-0.80), 0.77 (0.70-0.82), and 0.82 (0.78-0.87) for the mpMRI-based DL model, PET/CT-based DL model, and the combined mpMRI + PET/CT multimodal DL model, respectively. In the external test set (Center 2), the AUCs for these models were 0.75 (0.60-0.88), 0.77 (0.72-0.88), and 0.81 (0.63-0.97), respectively. The multimodal DL model demonstrated superior predictive accuracy compared to single-modality models in both internal and external validations. The deep learning-assisted EPE-grade scoring model significantly improved AUC and sensitivity compared to radiologist EPE-grade scoring alone (P < 0.05), with a modest reduction in specificity. Additionally, the deep learning-assisted scoring model provided greater clinical net benefit than the radiologist EPE-grade score used by radiologists alone. CONCLUSION: The multimodal imaging deep learning model, integrating mpMRI and 18 F-PSMA PET/CT, demonstrates promising predictive performance for EPE in prostate cancer and enhances the accuracy of radiologists in EPE assessment. The model holds potential as a supportive tool for more individualized and precise therapeutic decision-making.